# A Proinflammatory Psoriatic Microenvironment Has Early Effects on Keratinocyte Proliferation/Differentiation and Induces Ferroptosis in HaCaT Cells

**Authors:** Federica Riva, Elena Gammella, Margherita Correnti, Davide Daluiso, Francesca Prignano, Stefania Recalcati, Elena Donetti

PMC · DOI: 10.3390/biology15040362 · Biology · 2026-02-21

## TL;DR

This study explores how a proinflammatory environment affects skin cells in psoriasis, revealing early changes in cell function and a process called ferroptosis.

## Contribution

The paper introduces a novel experimental model of the psoriatic microenvironment and identifies ferroptosis as a key mechanism in early psoriasis development.

## Key findings

- The proinflammatory cytokine mix reduced CLDN-1 and ZO-1 in HaCaT cells, indicating impaired cell adhesion.
- Ferroptosis was triggered by increased intracellular iron and reduced GPX4 and GSH levels.
- Proliferation of HaCaT cells was reduced after exposure to the cytokine mix.

## Abstract

Psoriasis is a chronic immune-mediated skin disease with a highly negative impact on quality of life. It is important to fill the gap between the well-known specific skin plaques and the scenario which takes place before we can visualize them. This can be achieved by using suitable experimental models. This paper shows an experimental model of psoriatic cells’ microenvironment and some pathogenetic mechanism of the lesion evaluation, such as, for example, ferroptosis. Ultimately, but not less importantly, the key goal of this effort is to plan an appropriate and targeted therapeutic treatment.

Background: The interaction between keratinocytes and proinflammatory cytokines is essential in the development of psoriatic lesions. The synergism among these cytokines and their involvement in ferroptosis are not yet elucidated. This study aimed at evaluating the early impact of a complete proinflammatory microenvironment on keratinocyte differentiation, intercellular adhesion, proliferation, and induction of ferroptosis. Methods: HaCaT cells were differentiated with 1.8 mM CaCl2 and treated with a cytokine combination (MIX) containing IL-17A, IL-22, IL-23, and TNF-alpha for 24 and 48 h. Claudin 1 (CLDN-1), Zonula Occludens 1 (ZO-1), and keratins (K)10/K14 expression was analyzed by immunofluorescence and immunoblot analysis, paralleled by proliferation and ultrastructural analysis. Ferroptosis was induced with erastin and RSL3 and evaluated by testing glutathione (GSH)/glutathione peroxidase 4 (GPX4) protein expression, GSH levels, cell availability/toxicity, intracellular iron and ATP levels. Results: After MIX incubation at T48, CLDN-1 and ZO-1 immunofluorescences were reduced in HaCaT cells, while K10 and K14 were unaffected. The proliferative activity was reduced. Psoriatic-like MIX triggered the ferroptotic pathway, as shown by the increase in intracellular iron levels as well as by the reduction in GPX4 protein expression, the decrease in GSH levels, cell availability, and ATP levels. Conclusions: This experimental model mimics the early pathogenetic processes underlying psoriatic plaque formation/progression paving the way for new therapeutic strategies.

## Linked entities

- **Genes:** CLDN1 (claudin 1) [NCBI Gene 9076], TJP1 (tight junction protein 1) [NCBI Gene 7082], KRT10 (keratin 10) [NCBI Gene 3858], KRT14 (keratin 14) [NCBI Gene 3861], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879]
- **Proteins:** CLDN1 (claudin 1), TJP1 (tight junction protein 1), GPX4 (glutathione peroxidase 4)
- **Chemicals:** CaCl2 (PubChem CID 5284359), erastin (PubChem CID 11214940), RSL3 (PubChem CID 1750826), glutathione (PubChem CID 124886), ATP (PubChem CID 5957)
- **Diseases:** psoriasis (MONDO:0005083)

## Full-text entities

- **Genes:** IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IL37 (interleukin 37) [NCBI Gene 27178] {aka FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H, IL-1H4}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, MIXL1 (Mix paired-like homeobox) [NCBI Gene 83881] {aka MILD1, MIX, MIXL}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, KRT17 (keratin 17) [NCBI Gene 3872] {aka 39.1, CK-17, K17, PC2, PCHC1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, KRT10 (keratin 10) [NCBI Gene 3858] {aka BCIE, BIE, CK10, EHK, EHK2, EHK2A}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, HSPD1 (heat shock protein family D (Hsp60) member 1) [NCBI Gene 3329] {aka CPN60, GROEL, HLD4, HSP-60, HSP60, HSP65}, OSM (oncostatin M) [NCBI Gene 5008], KRT14 (keratin 14) [NCBI Gene 3861] {aka CK14, EBS1, EBS1A, EBS1B, EBS1C, EBS1D}, FLG (filaggrin) [NCBI Gene 2312] {aka ATOD2, FLG-1, FLG1}, FGF7 (fibroblast growth factor 7) [NCBI Gene 2252] {aka HBGF-7, KGF}
- **Diseases:** TD (MESH:D007153), Cytotoxicity (MESH:D064420), skin disease (MESH:D012871), mitochondrial damage (MESH:D028361), inflammation (MESH:D007249), ultrastructural (MESH:C566368), hyperproliferative disease (MESH:D004194), injury to (MESH:D014947), Psoriatic (MESH:D015535), Psoriasis (MESH:D011565)
- **Chemicals:** HEPES (MESH:D006531), penicillin (MESH:D010406), Erastin (MESH:C477224), cystine (MESH:D003553), DMEM (-), uranyl acetate (MESH:C005460), MTT (MESH:C070243), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), ATP (MESH:D000255), L-Glutamine (MESH:D005973), CO2 (MESH:D002245), GSH (MESH:D005978), ROS (MESH:D017382), calcium (MESH:D002118), sodium tetraborate (MESH:C010634), Tween-20 (MESH:D011136), PBS (MESH:D007854), glutaraldehyde (MESH:D005976), osmium tetroxide (MESH:D009993), NaCl (MESH:D012965), polyacrylamide (MESH:C016679), streptomycin (MESH:D013307), lipid peroxide (MESH:D008054), FITC (MESH:D016650), 5-bromo-2'-deoxyuridine (MESH:D001973), NP-40 (MESH:C010615), araldite (MESH:C005752), EDTA (MESH:D004492), Iron (MESH:D007501), TBS (MESH:D013725), Hoechst 33258 (MESH:D006690), water (MESH:D014867), ethanol (MESH:D000431), CaCl2 (MESH:D002122), HCl (MESH:D006851), SDS (MESH:D012967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Armoracia rusticana (horseradish, species) [taxon 3704], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** S100C
- **Cell lines:** HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), NHEK — Homo sapiens (Human), Finite cell line (CVCL_9Q50)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937887/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937887/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937887/full.md

---
Source: https://tomesphere.com/paper/PMC12937887